SRZN Surrozen Inc

$SRZN is this a short squeeze in the making? I'm seeing an above 100% cost to borrow, 30% of the float sold short and 9 days to cover...just missing that nice big catalyst to light the fire

$SRZN another deal that could put more pressure on Regeneron and the other potential acquirers. https://www.businesswire.com/news/home/20261008992641/en/Glaukos-Announces-Exclusive-License-Agreement-with-RevOpsis-Therapeutics-to-Develop-and-Commercialize-RO-104-a-First-in-Class-Tri-Specific-Biologic-for-Retinal-Diseases

$SRZN Boxer Capital bought more shares after Brunello results and went over 10% ownership. They now still have to publish the Form 3 filing in the next days.

$SRZN — Surrozen is taking an interesting approach to diabetic macular edema with SZN-8141. Instead of relying solely on VEGF inhibition, the drug combines VEGF inhibition with activation of the Wnt pathway, potentially addressing vascular damage through two mechanisms. The IND has been submitted, making clinical clearance and first-patient dosing the next milestones I’m interested in.

$SRZN so the potential acquirers have until October 20 to sign a buyout transaction or Surrozen will continue on their own with $95 million more cash.

$SRZN — Surrozen's recent analyses focused on its significant revenue growth, FDA clearance for SZN-8141, and a substantial private placement.

$SRZN succeeded in closing its second tranche, raising about $95.1M and meeting the FDA clearance milestone.

$SRZN 💰 Surrozen, Inc. closed the second and final tranche of its March 2025 private placement, generating approximately $95.1 million in gross proceeds to strengthen its balance sheet and extend cash runway into 2029. Actionable market event

Guggenheim Securities named Surrozen its top biotechnology pick, assigning a Buy rating and a $42 price target, implying substantial upside from its approximately $730 million market capitalization. The investment thesis centers on SZN-8141, an experimental treatment for retinal vascular diseases that combines Wnt pathway activation with anti-VEGF therapy in a single molecule. Management aims to position it as a premium first-line biologic competing with established treatments such as Vabysmo. Guggenheim views 2027 as a pivotal year for Surrozen. The company plans to initiate the Phase Ib/IIa DUET study of SZN-8141 before the end of 2026, with initial data expected in the second half of 2027. The trial will test whether combining Wnt activation and anti-VEGF activity can improve treatment efficacy and durability. Management also discussed Merck’s BRUNELLO study, which supported Wnt activation as a potential non-VEGF mechanism in retinal disease treatment. $SRZN

$SRZN ...based on the presentation and published official results by Merck yesterday...we could see either 16-18 tomorrow or 35-40...I'm ready for both opportunities...

$SRZN .....Saturday AAO = binary moment. Merck’s Wnt data decides srzn fate for Monday: • Flop / toxic safety tables ➡️ dump to $10-$12 (PIPE floor) • Home run on vessel reperfusion ➡️ squeeze to $50+ Zero human data for 8141 means SRZN trades 100% on Merck's coattails this weekend.

$SRZN I’ve tended to follow your updates on this one. Hoping for a buyout prior to the 20th but if a buyout doesn’t happen would you expect price to drop all the way back to the $11.60? Curious as I have held out in hopes of a buyout but it is feeling very uncertain on price movement

$SRZN, an eye-drug developer with no approved products, got FDA clearance to test SZN-8141 in diabetic eye disease. That triggers about $95.1 million of new stock sales on or about October 20, at $11.60 a share, a price set in March 2025, while the stock closed at $29.375. It gets cash about equal to its June balance. Buyers get stock at well under half the market price. Common shares rise about 49%, or about 63% counting pre-funded warrants before 4,099,052 new warrants at $11.54. Early trial data is due in the second half of 2027.

$SRZN Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema